Publikationen, an denen er mitarbeitet Elisa Luño Fernández (13)

2018

  1. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

    British Journal of Haematology, Vol. 181, Núm. 3, pp. 350-359

2017

  1. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group

    Leukemia Research, Vol. 63, pp. 85-89

  2. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)

    American Journal of Hematology, Vol. 92, Núm. 7, pp. 614-621

  3. Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group

    American Journal of Hematology, Vol. 92, Núm. 9, pp. E534-E541

2016

  1. Considering bone marrow blasts from nonerythroid cellularity improves the prognostic evaluation of myelodysplastic syndromes

    Journal of Clinical Oncology, Vol. 34, Núm. 27, pp. 3284-3292

  2. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: A rationale for its inclusion into future classifications of myelodysplastic syndromes

    Modern Pathology, Vol. 29, Núm. 12, pp. 1541-1551

  3. Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia

    European Journal of Haematology, Vol. 97, Núm. 1, pp. 33-38

2015

  1. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: A population-based study

    The Lancet Haematology, Vol. 2, Núm. 6, pp. e260-e266

2014

  1. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

    British Journal of Haematology, Vol. 166, Núm. 2, pp. 189-201

  2. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome

    Leukemia Research, Vol. 38, Núm. 5, pp. 551-556

  3. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis

    Leukemia Research, Vol. 38, Núm. 3, pp. 304-309

2013

  1. Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing

    Genes Chromosomes and Cancer, Vol. 52, Núm. 12, pp. 1167-1177

2011

  1. Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study

    Leukemia Research, Vol. 35, Núm. 9, pp. 1184-1187